Skip to Content

CRISPR Therapeutics AG CRSP

Morningstar Rating
$68.16 −2.00 (2.85%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Crispr Earnings: Blockbuster Potential for Casgevy; Shares Undervalued for Long-Term Investors

Crispr Therapeutics has achieved many recent milestones, most notably the approval of Casgevy for the treatment of patients with sickle cell disease or transfusion-dependent beta thalassemia. Clinical trials are advancing for its early-stage pipeline with candidates evaluating the treatment of Type 1 diabetes, liquid and solid tumors, and cardiovascular diseases. We maintain our positive long-term outlook and $119 fair value estimate. We view the stock as undervalued, trading in 4-star territory about 30% below our fair value estimate. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

Price vs Fair Value

CRSP is trading at a 40% discount.
Price
$71.08
Fair Value
$981.00
Uncertainty
Very High
1-Star Price
$985.99
5-Star Price
$73.30
Economic Moat
Nszwx
Capital Allocation
Bzcvxyhd

Bulls Say, Bears Say

Bulls

Partnerships allow CRISPR Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Besides exa-cel, CRISPR Therapeutics’ pipeline is largely in the early stages of development and several years away from potentially receiving approval.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRSP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$70.16
Day Range
$67.5270.12
52-Week Range
$37.5591.10
Bid/Ask
$68.00 / $68.38
Market Cap
$5.47 Bil
Volume/Avg
1.6 Mil / 2.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
14.59
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
407

Competitors

Valuation

Metric
CRSP
BNTX
VRTX
Price/Earnings (Normalized)
28.3227.46
Price/Book Value
2.900.986.13
Price/Sales
14.595.4211.03
Price/Cash Flow
28.63
Price/Earnings
CRSP
BNTX
VRTX

Financial Strength

Metric
CRSP
BNTX
VRTX
Quick Ratio
17.419.123.60
Current Ratio
17.549.433.99
Interest Coverage
86.38
Quick Ratio
CRSP
BNTX
VRTX

Profitability

Metric
CRSP
BNTX
VRTX
Return on Assets (Normalized)
−3.61%3.43%19.46%
Return on Equity (Normalized)
−4.34%3.85%25.47%
Return on Invested Capital (Normalized)
−3.83%2.43%21.34%
Return on Assets
CRSP
BNTX
VRTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRClxddyvxnFgs$570.1 Bil
VRTX
Vertex Pharmaceuticals IncBxlbgcbdWxnvsz$108.0 Bil
REGN
Regeneron Pharmaceuticals IncPhdgbjkwwCpnnx$105.6 Bil
MRNA
Moderna IncBwrpqxrsTmyy$40.8 Bil
ARGX
argenx SE ADRZmbpvmyjnMlmv$23.5 Bil
BNTX
BioNTech SE ADRLrycvkqhCvyb$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncZmnlhxdzThtlf$18.8 Bil
BMRN
Biomarin Pharmaceutical IncWbjxhmjntBwfkp$16.5 Bil
RPRX
Royalty Pharma PLC Class AFgxvnjzpWtgyyj$13.6 Bil
INCY
Incyte CorpHyvfrglyMjzjs$12.8 Bil

Sponsor Center